73 completed, 15 terminated, 15 unknown, 7 recruiting. 36 Phase 3, 23 Phase 4, 21 Phase 2, 8 Phase 1, 7 Not applicable.
Follow golimumab: new trials by email Literature Review of golimumab trials Research Report on golimumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo Golimumab, Placebo (matching golimumab) - Type 1 Diabetes (T1D) | Phase 2 | Not yet recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 255 | 2026-08-08 | 2026-07-06 |
| Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population Non-Interventional Study - Ulcerative Colitis | Active not recruiting | Pfizer | 4000 | 2026-04-01 | 2026-10-15 | |
| Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt adalimumab, infliximab, ustekinumab, golimumab, and vedolizumab - Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis) | Not yet recruiting | Assiut University | 95 | 2026-03-01 | 2026-03-27 | |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease This is an observational study with no intervention. Patients will receive anti- TNF therapy as part of their standard care - IBD (Inflammatory Bowel Disease), Crohn Disease (CD) | Recruiting | Shmuel Kivity, MD | 40 | 2025-01-04 | 2026-06-12 | |
| Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study Apalutamide, Biopsy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Terminated | University of Washington | 8 | 2024-05-23 | 2026-10-19 |
| Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success Ozanimod, TNF Inhibitor, Steroids - Ulcerative Colitis | Unknown | Insel Gruppe AG, University Hospital Bern | 240 | 2023-09-06 | 2023-12-06 | |
| Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients Guselkumab, Golimumab - Psoriatic Arthritis | Phase 3 | Recruiting | University of Pennsylvania | 63 | 2023-07-14 | 2025-10-09 |
| Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX AVT05 (proposed biosimilar to golimumab), Simponi (Golimumab) - Rheumatoid Arthritis | Phase 3 | Completed | Alvotech Swiss AG | 502 | 2023-03-30 | 2024-10-02 |
| The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients Anti-TNF, JAK inhibitor - Rheumatoid Arthritis | Phase 3 | Withdrawn | Abu Dhabi Stem Cells Center | 2023-03-01 | 2025-10-06 | |
| Stand UP to Rheumatoid Arthritis (SUPRA) TNFi, Anti-IL6, JAKi - Rheumatoid Arthritis | Not applicable | Recruiting | Marie Hudson, MD | 75 | 2023-02-01 | 2026-02-03 |
| A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants AVT05, Simponi - Healthy Adult Subjects | Phase 1 | Completed | Alvotech Swiss AG | 336 | 2022-12-16 | 2025-05-28 |
| A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis Guselkumab, Golimumab, JNJ-78934804 - Colitis, Ulcerative | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 577 | 2022-09-19 | 2026-09-28 |
| A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi® BAT2506 injection, Simponi® (EU commercially available product), Simponi® (US commercially available product) - Psoriatic Arthritis | Phase 1 | Completed | Bio-Thera Solutions | 375 | 2022-08-01 | 2023-08-28 |
| A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease Guselkumab, Golimumab, JNJ-78934804 - Crohn's Disease | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 703 | 2022-07-22 | 2026-09-28 |
| Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD) - Rheumatoid Arthritis | Not applicable | Unknown | Medical University of Vienna | 85 | 2022-03-01 | 2021-11-15 |
| REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) Adalimumab and its biosimilars, Biological: Etanercept and its biosimilars, Golimumab - Ankylosing Spondylitis, Axial Spondyloarthritis | Phase 4 | Unknown | Hanyang University Seoul Hospital | 448 | 2022-01-15 | 2021-12-20 |
| Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis Tapered doses of TNFi, Standard dose of TNFi - Axial Spondyloarthritis | Phase 4 | Unknown | University Health Network, Toronto | 15 | 2021-12-01 | 2024-01-17 |
| A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis Guselkumab, Golimumab, Placebo - Arthritis, Psoriatic | Phase 2 | Completed | Janssen Research & Development, LLC | 91 | 2021-10-25 | 2026-07-23 |
| Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D Golimumab, Placebo - Diabetes Mellitus, Type 1 | Phase 2 | Withdrawn | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2021-07-01 | 2021-12-02 |
Showing 20 of 121. Sign in to see all of them.
Arthritis, Rheumatoid (41) · Colitis, Ulcerative (25) · Arthritis, Psoriatic (18) · Spondylitis, Ankylosing (18) · Spondylarthritis (8) · Axial Spondyloarthritis (5) · Crohn Disease (5) · Diabetes Mellitus, Type 1 (5) · Inflammatory Bowel Diseases (5) · Spondylarthropathies (4) · Arthritis (3) · Arthritis, Juvenile (3) · Arthralgia (2) · Asthma (2) · Infections (2)
Janssen Research & Development, LLC (18) · Centocor, Inc. (16) · Merck Sharp & Dohme LLC (7) · Janssen Biotech, Inc. (3) · Janssen Pharmaceutical K.K. (3) · Alvotech Swiss AG (2) · Brigham and Women's Hospital (2) · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa (2) · Janssen Inc. (2) · Janssen Scientific Affairs, LLC (2) · Medical University of Graz (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · University of Erlangen-Nürnberg Medical School (2) · Abu Dhabi Stem Cells Center (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)
United States (43) · Canada (24) · Germany (23) · Poland (21) · Belgium (19) · France (18) · United Kingdom (18) · Netherlands (16) · Russia (16) · Spain (16) · Hungary (15) · Ukraine (13) · Australia (12) · Czechia (12) · South Korea (12)
Carla Greenbaum, MD (2) · Alexis Ogdie-Beatty, MD, MSCE (1) · Anja Geldhof, Eng, Ph.D. (1) · Ayal Hirsch, MD (1) · Becky Ward (1) · Benjamin Misselwitz, Prof. (1) · Chang-Keun Lee, MD (1) · Changhoon Lee, MD (1) · Chris Wynne (1) · Christian Dejaco, MD, PhD (1)
PMID 27803138, PMID 30412238, PMID 31982148, PMID 35313978, PMID 24757132, PMID 28606966, PMID 30225992, PMID 30721964, PMID 36995469, PMID 18383539, PMID 19136369, PMID 19560810, PMID 20131276, PMID 20506403, PMID 21083889, PMID 22089463, PMID 22121129, PMID 22127693, PMID 22169051, PMID 22378566, PMID 22505702, PMID 22740380, PMID 22776409, PMID 22984173, PMID 23024015, PMID 23418046, PMID 23666608, PMID 23678153, PMID 23735746, PMID 23740226, PMID 23770005, PMID 23861303, PMID 24001888, PMID 24127416, PMID 24501241, PMID 24729398, PMID 24748630, PMID 24786931, PMID 24839031, PMID 25005327, PMID 25034562, PMID 25387477, PMID 25428650, PMID 25539805, PMID 25594886, PMID 25623393, PMID 25627338, PMID 25664404, PMID 25779603, PMID 26119226
2009 (4), 2014 (4), 2015 (3), 2017 (3), 2023 (3), 2016 (2), 1UC4DK117009-01 (1), 2004 (1), 2005 (1), 2008 (1), U01DK106993 (1)